Nanomedicine Market Size to Reach US$ 389.52 Billion by 2033, Driven by Advancements in Targeted Therapies and Drug Delivery Innovations | According DataM Intelligence
Dateline: Austin, Texas and Tokyo, Oct. 13, 2025
The global nanomedicine market reached US$ 169.51 billion in 2024 and is expected to reach US$ 389.52 billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025–2033. Growth is being driven by rising chronic diseases, increasing demand for targeted therapies, and advances in drug delivery, mRNA vaccines, and gene editing.
North America currently dominates the nanomedicine market due to significant R&D investments by major pharmaceutical companies. Growth is supported by out-licensing activity, healthcare expansion in emerging markets, and innovations that improve diagnostics, drug delivery and personalized medicine. Industry–academia collaborations — for example, the 2022 Marble Center program with Alloy Therapeutics, Sanofi and others — are accelerating nanomedicine research and development.
AI Revolutionizes Nanomedicine by Enhancing Drug Design, Precision Delivery and Personalized Treatments
Artificial intelligence (AI) is enabling the design of nanomedicines with more precise therapeutic effects. AI and machine learning help predict key drug properties to optimize efficiency and safety. Advanced AI-based sensors and platforms allow healthcare providers to control and adjust drug dosing via mobile interfaces, enabling targeted and adjustable delivery. AI also supports real-time forecasting of treatment outcomes and personalized treatment adjustments. Overall, AI is accelerating drug development, improving treatment precision and supporting personalized medicine in nanomedicine.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/nanomedicine-market
Report details: 69 tables, 69 figures, ~180 pages.
Market Segments
By Application — Drug Delivery Leads: The drug delivery segment held a 32.1% share in 2024, supported by increasing incidence of chronic and infectious diseases and extensive research into nanoparticle- and nanocarrier-based delivery methods. The therapeutics segment is projected to grow fastest (estimated CAGR ~11.3% from 2025 to 2032) as novel nanotherapeutics that cross biological barriers progress through development.
By Indication — Oncology Leads; Infectious Diseases Growing Rapidly: Clinical oncology accounted for 30.44% of the market in 2024 as nanomedicine enables targeted cancer therapies that improve outcomes and reduce side effects. The infectious disease segment is forecast to expand at a ~12.31% CAGR through 2032, driven by need for more efficient, cost-effective and targeted treatments.
Regional Outlook
North America: North America led the market in 2024 with a 48.9% share. Leadership is backed by collaborations between established corporations and nanomedicine start-ups, strong government backing, and high R&D investment. Initiatives such as the U.S. National Nanotechnology Initiative (NNI) support basic and applied science, technology transfer and commercialization efforts.
Asia Pacific: Asia Pacific is expected to grow the fastest — projected CAGR of about 15% between 2025 and 2032 — supported by rising awareness, increased public engagement, major investment in research hubs and facilities (notably in China), and long-term national strategies to commercialize nanotechnology innovations.
Key Companies
Major players actively pursuing partnerships, M&A, geographic expansion and strategic alliances include Pfizer, CytImmune Sciences, Sanofi (Ablynx), Genentech, Moderna, Janssen Pharmaceutical, Amgen, Merck and Teva Pharmaceuticals. These companies are advancing the market via product launches, targeted acquisitions and collaborative R&D.
Purchase: The report is available for purchase; more details at https://www.datamintelligence.com/buy-now-page?report=nanomedicine-market
Recent Developments
- April 2025 — Nanopharmaceutics, Inc. announced initiation of a Phase 1 clinical study (sponsored by the U.S. National Cancer Institute) testing addition of the anti-cancer drug triapine to standard radiation therapy for recurrent glioblastoma or astrocytoma.
- August 2024 — VION Biosciences acquired Echelon Biosciences, expanding capabilities in lipid-based excipients for research, diagnostics and drug discovery.
- April 2024 — Nanoform Finland Plc entered a strategic partnership with CBC Co., Ltd. to leverage Japanese pharmaceutical industry expertise and identify opportunities for Nanoform’s nanomedicine engineering technologies.
Related Reports
- Nanotechnology in Drug Delivery Market Size
- Nanopharmaceuticals Market Size
- Nanorobotics Market Size
About DataM Intelligence 4Market Research
DataM Intelligence 4Market Research is a market intelligence platform offering syndicated and customized reports and consulting across industries including chemicals, healthcare, agriculture, F&B and more. The firm provides market insights, forecasts and tailored research solutions to help clients make informed decisions and commercialize innovations.
To learn more: https://www.datamintelligence.com/ — follow on Twitter, LinkedIn and Facebook.
Contact
Mr. Sai Kiran
DataM Intelligence 4Market Research LLP
Ground Floor, DSL Abacus IT Park, Industrial Development Area,
Uppal, Hyderabad, Telangana 500039, India
USA: +1 877-441-4866
Email: [email protected]
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
Source: DataM Intelligence 4 Market Research LLP